Brolucizumab-dbll injection, for intravitreal injection (Beovu®) HCPCS code J3590: Billing Guidelines

<p>Effective with date of service Oct. 10, 2019, the North Carolina Medicaid and NC Health Choice programs cover brolucizumab-dbll injection, for intravitreal injection (Beovu) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3590 - Unclassified biologics.</p>

Author: GDIT, (800) 688-6696

Effective with date of service Oct. 10, 2019, the North Carolina Medicaid and NC Health Choice programs cover brolucizumab-dbll injection, for intravitreal injection (Beovu) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3590 - Unclassified biologics.

For Medicaid and NC Health Choice Billing

  • The ICD-10-CM diagnosis code(s) required for billing are: H35.3211 - Exudative age-related macular degeneration, right eye, with active choroidal neovascularization; H35.3221 - Exudative age-related macular degeneration, left eye, with active choroidal neovascularization; H35.3231 - Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization; H35.3291 - Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization; H35.3212 - Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization; H35.3222 - Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization; H35.3232 - Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization; H35.3292 - Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization; H35.3213 - Exudative age-related macular degeneration, right eye, with inactive scar; H35.3223 - Exudative age-related macular degeneration, left eye, with inactive scar; H35.3233 - Exudative age-related macular degeneration, bilateral, with inactive scar; H35.3293 - Exudative age-related macular degeneration, unspecified eye, inactive scar; H35.3210 - Exudative age-related macular degeneration, right eye, with stage unspecified; H35.3220 - Exudative age-related macular degeneration, left eye, with stage unspecified; H35.3230 - Exudative age-related macular degeneration, bilateral, with stage unspecified; H35.3290 - Exudative age-related macular degeneration, unspecified eye, stage unspecified
  • Providers must bill with HCPCS code: J3590 - Unclassified biologics
  • One Medicaid and Health Choice unit of coverage is: 1 mg
  • The maximum reimbursement rate per unit is: $333.00
  • Providers must bill 11-digit NDCs and appropriate NDC units. The NDC is: 00078-0827-61
  • The NDC units should be reported as "UN1."
  • For additional information, refer to the January 2012, Special Bulletin, National Drug Code Implementation Update.
  • For additional information regarding NDC claim requirements related to the PADP, refer to the PADP Clinical Coverage Policy 1B, Attachment A, H.7 on DHB's website.
  • Providers shall bill their usual and customary charge for non-340B drugs.
  • PADP reimburses for drugs billed for Medicaid and NC Health Choice beneficiaries by 340B participating providers who have registered with the Office of Pharmacy Affairs (OPA).  Providers billing for 340B drugs shall bill the cost that is reflective of their acquisition cost. Providers shall indicate that a drug was purchased under a 340B purchasing agreement by appending the "UD" modifier on the drug detail.
  • The fee schedule for the PADP is available on DHB's PADP web page.

Related Topics: